American Society of Hematology Meeting 2014: CMRG 001
First Report of the Myeloma Canada Research Network (MCRN)-001 Trial UtilizingBortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan(BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Basedon Achievement of Minimal Residual Disease (MRD) Negativity
American Society of Hematology Meeting 2015: CMRG 001
Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite chain (HLC) Normalization
International Myeloma Workshop Meeting 2015: CMRG 001
Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)
American Society of Hematology Meeting 2016: CMRG 002
Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial
American Society of Hematology Meeting 2016: CMRG 001
Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan(BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated ResultsIncluding Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain(HLC) Ratio Assessments
American Society of Hematology Meeting 2018: CMRG 003
A single arm phase II study of high-dose weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 prior therapies
American Society of Hematology Meeting 2019: CMRG 004
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma
American Society of Hematology Meeting 2020: CMRG 004
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma
International Myeloma Workshop 2019: CMRG 007
The ALGONQUIN Study: A Phase 1/2 Multi-Center, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination with Pomalidomide and Low Dose Dexamethasone in Subjects with RRMM
European Hematology Association Congress 2020: CMRG 007
Phase 1/2 Study of Belantamab mafodotin in Combination with Pomalidomide and Dexamethasone: Results for Part 1 Dose Finding
American Society of Hematology Meeting 2020: CMRG 007
Part 1 Results of a Dose Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
International Myeloma Workshop 2021: CMRG 007
Extended Follow-Up Safety and Efficacy Results of Belantamab Mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg Combined with Pom and Dex for the Treatment of Relapsed/Refractory Multiple Myeloma
International Myeloma Workshop 2019: CMRG 009
Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Real-World Evidence
European Hematology Association Meeting 2018
The Myeloma Canada Research Network Canadian Multiple Myeloma Database (MCRN CMM-DB): Multi-Institutional Sharing Of Clinical Data For Research
American Society of Hematology Meeting 2018
Real-world outcomes with bortezomib-containing regimens and lenalidomide and dexamethasone for the treatment of transplant ineligible MM patients: A multi-institutional report from the National Myeloma Canada Research Network (MCRN) database
European Journal of Hematology Vol. 105 Issue 5: May 2021
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma
Haematologica Vol. 106 No. 6: June, 2021
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
Journal of Cancer Immunology Vol. 3 Issue 1: 2021
Lenalidomide Maintenance After Autologous Stem Cell Transplant: The Utility of Real-World Data and Future Areas of Study
British Journal of Haematology Vol. 193 Issue 3: May 2021
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database
European Hematology Association Meeting 2019
Lenalidomide maintenance positively impacts outcomes in multiple myeloma without negative impacts in relapse: An analysis of Real World Data from the Myeloma Canada Research Network National Database
International Myeloma Workshop 2019
The impact of lenalidomide maintenance on second line chemotherapy in transplant eligible patients with multiple myeloma in the Canadian setting
American Society of Hematology Meeting 2019
Treatment of myeloma patients progressing on lenalidomide-based maintenance after ASCT performed as part of 1st, 2nd or 3rd line therapy: Real-World results from the National Myeloma Canada Research Network Database
European Hematology Association Meeting 2019
Treatment of multiple myeloma patients progressing on lenalidomide-based regimens
American Society of Hematology Meeting 2020
Efficacy of daratumumab containing regimens post lenalidomide maintenance in transplant eligible patients: Real-World Experience from the Canadian Myeloma Research Group Database
American Society of Hematology Meeting 2020
Sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
American Society of Hematology Meeting 2020
Maintenance therapy but not tandem autologous stem cell transplant (ASCT) improves outcomes in multiple myeloma with high-risk cytogenetics: Results from the Canadian Myeloma Research Group (CMRG) Database
American Society of Hematology Meeting 2020
Efficacy of daratumumab containing regimens post lenalidomide maintenance in transplant eligible patients: Real-World Experience from the Canadian Myeloma Research Group Database
American Society of Hematology Meeting 2020
Sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
European Hematology Association Meeting 2021
Carfilzomib-containing regimens for relapsed multiple myeloma in a Real-World setting: A multi-institutional report from the Canadian Myeloma Research Group (CMRG)
European Hematology Association Meeting 2021
Survival and outcomes of newly-diagnosed multiple myeloma patients stratified by transplant status diagnosed between 2007-2018: Real-World analysis from the Canadian Myeloma Research Group Database
European Hematology Association Meeting 2021
Outcomes of daratumumab-containing regimens in the treatment of relapsed multiple myeloma: Real-World data from the Canadian Myeloma Research Group Database
European Journal of Haematology Vol. 107 Issue 4: October 2021
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada
